UMMS Team Publishes In Vitro, In Vivo Data on Oral siRNA-Delivery Tech

The technology, called glucan-encapsulated siRNA particles, or GERPs, has been exclusively licensed by RXi Pharmaceuticals for use in developing RNAi-based therapeutics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories